Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.44−0.16 (-6.15%)
Close on Nov 20, 2026Market cap $84.82MP/E –Yield –
Anixa Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Anixa Biosciences's free cash flow for the twelve months ending Oct 31, 2020 was -$6.19M. For fiscal 2020 it was -$6.19M. The highest annual figure on record is $1.31M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Oct 31, 2020 | -$6.19M | – |
| FY2019 | Oct 31, 2019 | -$4.92M | – |
| FY2018 | Oct 31, 2018 | -$4.31M | – |
| FY2017 | Oct 31, 2017 | -$3.83M | – |
| FY2016 | Oct 31, 2016 | -$3.53M | -369.6% |
| FY2015 | Oct 31, 2015 | $1.31M | – |
| FY2014 | Oct 31, 2014 | -$2.39M | – |
| FY2012 | Oct 31, 2012 | -$3.14M | – |
| FY2011 | Oct 31, 2011 | -$725.03K | – |
| FY2010 | Oct 31, 2010 | -$2.41M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -$1.41M | – |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -$1.29M | – |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -$1.56M | – |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -$1.93M | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -$1.34M | – |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -$640.10K | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -$1.03M | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -$1.19M | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$751.78K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$1.34M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$752.59K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$1.25M | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$1.08M | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$744.03K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$684.87K | – |
See a number that looks wrong?